Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Myocardial IschemiaCoronary Artery DiseaseEndothelial Dysfunction
Interventions
DRUG

Ticagrelor

Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).

DRUG

Clopidogrel

Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).

Trial Locations (1)

Unknown

University Hospital Limerick, Dooradoyle

All Listed Sponsors
lead

University Hospital of Limerick

OTHER

NCT02469740 - Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI | Biotech Hunter | Biotech Hunter